HC Wainwright Forecasts Weaker Earnings for Pharming Group
Analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for shares of Pharming Group in a research note ...
Hosted on MSN1d
Encore Healthcare: Pharming the Future
There is never a perfect time to do an interview, so carpe diem! It was a Monday morning; having managed to block the ...
Nasdaq28d
Where Pharming Stands With Analysts
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick ...
Business Insider19d
Pharming Group reports third quarter 2024 financial results and provides business update
Chief Executive Officer, Sijmen de Vries, commented: “Pharming has delivered an excellent third quarter, increasing quarterly revenues by 12% to a record-high US$74.8 million and also achieving ...
Hosted on MSN19d
Pharming Group’s Strong Q3 and CEO Transition
Pharming Group (PHGUF) has released an update. Pharming Group has reported a strong third quarter in 2024, with total revenues rising by 12% to $74.8 million, driven by growth in its RUCONEST ...
Nasdaq15d
Pharming price target lowered to $30 from $31 at Oppenheimer
Oppenheimer analyst Jeff Jones lowered the firm’s price target on Pharming (PHAR) to $30 from $31 and keeps an Outperform rating on the shares following quarterly results and business update.
Pharming price target lowered to EUR 1.60 from EUR 1.65 at RBC Capital
RBC Capital lowered the firm’s price target on Pharming (PHAR) to EUR 1.60 from EUR 1.65 and keeps an Outperform rating on the shares.
CNN1y
Pharming Group NV ADR RegS
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST ...